Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

3.34 -5.38

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.34

Max

3.5300000000000002

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.4M -21M
Pārdošana	-8.8M 1.4M
P/E Sektora vidējais	22.5 56.597
EPS	-0.09
Peļņas marža	-1,457.405
Darbinieki	69
EBITDA	-2.4M -20M

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	118M 808M
Iepriekšējā atvēršanas cena	8.72
Iepriekšējā slēgšanas cena	3.34

Ziņu noskaņojums

By Acuity

50%

146 / 339 Rangs Healthcare

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. sept. 20:07 UTC

CytomX Therapeutics Inc shares declined during Thursday's session, continuing a downward trend with no specific news identified to explain the movement.

2026. g. 9. sept. 19:26 UTC

CytomX Therapeutics shares are lower during Wednesday's session, continuing a decline since Tuesday's close, amid broader market reactions to rising crude oil prices.

2026. g. 8. sept. 23:01 UTC

CytomX Therapeutics Inc shares are higher in after-market trading, maintaining a strong position above its 20-day moving average amid broader market trends.

2026. g. 4. sept. 20:07 UTC

CytomX Therapeutics Inc shares are higher during Friday's session, recovering from an earlier dip and remaining above the 20-day moving average.

2026. g. 2. sept. 20:08 UTC

Social Media

CytomX Therapeutics shares are higher, supported by Piper Sandler's $12 price target and positive sentiment in the Biotechnology sector ahead of upcoming data releases.

2026. g. 1. sept. 20:01 UTC

Social Media

News

CytomX Therapeutics is trading higher as it announces participation in key investor conferences and growing fund interest ahead of upcoming data releases.

2026. g. 31. aug. 20:07 UTC

CytomX Therapeutics is trading higher, following broader market gains since Friday. No specific company news was identified to explain the increase.

2026. g. 28. aug. 19:51 UTC

Event

CytomX Therapeutics shares are lower despite FDA granting Fast Track Designation for Varseta-M to treat metastatic colorectal cancer. Trading volume is unusually high.

2026. g. 27. aug. 23:02 UTC

Event

CytomX Therapeutics received Fast Track Designation for Varseta-M, yet shares are trading lower in after-market hours, breaking a recent trend of gains.

2026. g. 25. aug. 19:56 UTC

CytomX Therapeutics is trading higher amid positive market conditions and lower crude oil prices, which have decreased treasury yields and boosted investor sentiment.

2026. g. 24. aug. 19:26 UTC

CytomX Therapeutics is trading higher, reflecting gains since Friday's close. Earlier, shares peaked with a gain before pulling back to a modest advance.

2026. g. 21. aug. 19:46 UTC

CytomX Therapeutics Inc. is gaining during Friday's session, despite earlier volatility. No specific company news was identified to explain today's price movement.

2026. g. 20. aug. 21:01 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, reflecting unusual trading activity. The stock is positioned around the midpoint of its one-month range.

2026. g. 19. aug. 20:02 UTC

CytomX Therapeutics is trading higher during Wednesday's session, continuing a strong upward move since Tuesday's close amid notable volatility.

2026. g. 14. aug. 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

2026. g. 13. aug. 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

2026. g. 12. aug. 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

2026. g. 11. aug. 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

2026. g. 10. aug. 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

2026. g. 7. aug. 19:16 UTC

Social Media

News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

2026. g. 6. aug. 22:02 UTC

Social Media

News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

2026. g. 31. jūl. 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

2026. g. 29. jūl. 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

2026. g. 28. jūl. 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

2026. g. 27. jūl. 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

2026. g. 21. jūl. 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

146 / 339 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.